Trade EXEL stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Exelixis, Inc. (EXEL) is trading at US$59.86, up 1.42% today as of Oct 9, 16:00 EDT. The company has a market capitalisation of US$13.4B. Over the past 52 weeks, EXEL has traded between US$33.76 and US$61.14. On Syfe you can trade EXEL with $0 commission and add it to your watchlist.
| Previous close | US$59.02 |
|---|---|
| Market cap | US$13.4B |
| P/E ratio | 14.95 |
| 52-week range | US$33.76 – US$61.14 |
| Volume | 2.66M |
| Exchange | US |
Exelixis, Inc.
Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Year: 2000
Exelixis, Inc. (EXEL) stock is trading at US$59.86, +1.42% from the previous close of US$59.02.
The market cap for Exelixis, Inc. (EXEL) stock is approximately US$13.4B.
The price-to-earnings ratio for Exelixis, Inc. (EXEL) is 14.95, based on the latest reported earnings.
The 52-week high for Exelixis, Inc. (EXEL) stock is US$61.14.
The 52-week low for Exelixis, Inc. (EXEL) stock is US$33.76.
Exelixis, Inc. (EXEL) does not currently pay a dividend.
Stay on top of EXEL
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
